The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...
Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...
It hasn’t been an easy road for Joey Wilson. He says he’s dealt with the odds being against him since he was born prematurely ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Ottawa Citizen on MSN1d
Study finds 'concerning link' between hospital visits for psychedelic use and schizophreniaThe research, led by Dr. Daniel Myran, a Canada Research Chair in Social Accountability at the University of Ottawa, followed ...
ED visits related to hallucinogen use are linked to a 21-fold increased risk of schizophrenia spectrum disorder, results of a ...
Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
A larger, modern clubhouse replaced Club Nova’s nearly 100-year-old mill home that was packed with programs, members.
A new study from ICES and University of Ottawa reveals a 21-fold increase in schizophrenia risk following emergency visits ...
In the EMPOWER trials, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial. The most commonly reported adverse events in EMPOWER-1 and EMPOWER-2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback